We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sysco
SYY
$39.7B
| $437M | 0.91% |
11,676,115
+1,670,067
| +17% | +$61.3M |
|
27
APA Corp
APA
$12.8B
| $425M | 0.89% |
4,221,649
-351,711
| -8% | -$31.9M |
|
28
UnitedHealth
UNH
$382B
| $419M | 0.88% |
5,125,381
-136,794
| -3% | -$10.8M |
|
29
PG&E
PCG
$47.8B
| $418M | 0.87% |
8,700,791
+2,509,623
| +41% | +$114M |
|
30
Vale
VALE
$62.9B
| $416M | 0.87% |
31,436,688
+367,965
| +1% | +$4.97M |
|
31
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $412M | 0.86% |
2,104,560
+283,969
| +16% | +$54M |
|
32
Citigroup
C
$222B
| $408M | 0.85% |
8,653,427
+812,260
| +10% | +$38.6M |
|
33
American Express
AXP
$223B
| $402M | 0.84% |
4,237,512
-32,136
| -0.8% | -$2.9M |
|
34
Eli Lilly
LLY
$1.07T
| $400M | 0.84% |
6,434,958
-10,854
| -0.2% | -$648K |
|
35
Honeywell
HON
$77.1B
| $394M | 0.82% |
4,711,821
-113,680
| -2% | -$9.5M |
|
36
Baxter International
BAX
$11.6B
| $374M | 0.78% |
9,519,660
-225,631
| -2% | -$9.03M |
|
|
MON
37
DELISTED
Monsanto Co
MON
| $368M | 0.77% |
2,949,268
-105,522
| -3% | -$12.3M |
|
38
CEMIG Preferred Shares
CIG
$6.09B
| $367M | 0.77% |
90,034,389
+18,222,342
| +25% | +$69.2M |
|
39
Oracle
ORCL
$331B
| $318M | 0.67% |
7,851,983
-636,639
| -7% | -$26.2M |
|
40
Norfolk Southern
NSC
$78.8B
| $315M | 0.66% |
3,057,985
+1,349,000
| +79% | +$132M |
|
41
Amgen
AMGN
$203B
| $304M | 0.64% |
2,566,790
-91,633
| -3% | -$10.6M |
|
42
Johnson & Johnson
JNJ
$635B
| $301M | 0.63% |
2,876,253
-26,410
| -0.9% | -$2.67M |
|
|
CFN
43
DELISTED
CAREFUSION CORPORATION
CFN
| $300M | 0.63% |
6,754,802
-535,386
| -7% | -$22.2M |
|
44
Transocean
RIG
$5.92B
| $299M | 0.62% |
6,629,266
+111,314
| +2% | +$4.74M |
|
|
45
CVS Health
CVS
$137B
| $298M | 0.62% |
3,960,223
-3,171,687
| -44% | -$240M |
|
46
EOG Resources
EOG
$78B
| $298M | 0.62% |
2,546,128
-102,370
| -4% | -$10.8M |
|
47
ExxonMobil
XOM
$651B
| $294M | 0.61% |
2,919,550
-202,606
| -6% | -$20.4M |
|
48
Occidental Petroleum
OXY
$57B
| $291M | 0.61% |
2,955,564
-45,352
| -2% | -$4.26M |
|
49
Devon Energy
DVN
$51.9B
| $290M | 0.61% |
3,656,707
-147,267
| -4% | -$10.7M |
|
50
Intercontinental Exchange
ICE
$82.4B
| $290M | 0.61% |
7,678,525
+915,480
| +14% | +$35.7M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.